Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial

Clinical Cancer Research

Volumn 23, Issue 16, 2017, Pages 4651-4661

  Shaashua, Lee ^a   Shabat Simon, Maytal ^a   Haldar, Rita ^a   Matzner, Pini ^a   Zmora, Oded ^b   Shabtai, Moshe ^b   Sharon, Eran ^c   Allweis, Tanir ^d   Barshack, Iris ^b   Hayman, Lucile ^c   Arevalo, Jesusa ^e   Ma, Jeffrey ^e   Horowitz, Maya ^a   Cole, Steven ^e   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d KAPLAN MEDICAL CENTER   (Israel)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; EARLY GROWTH RESPONSE FACTOR 3; ETODOLAC; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; PLACEBO; PROPRANOLOL; STAT3 PROTEIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; LEUKOCYTE COUNT; LUMPECTOMY; MASTECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA EXTRACTION; TRANSCRIPTOMICS; BREAST TUMOR; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; ETODOLAC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PERIOPERATIVE PERIOD; PROPRANOLOL; TRANSCRIPTION FACTORS;

EID: 85027548181     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-0152     Document Type: Article

References (59)

1. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013;39:61–73.
2. Neeman E, Ben-Eliyahu S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun 2013;30:S32–40.
3. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003;10:972–92.
4. Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol 2015;12:213–26.
5. Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, et al. Adrenergic regulation of monocyte che-motactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget 2015;6:4266–73.
6. Neeman E, Zmora O, Ben-Eliyahu S. A new approach to reducing post-surgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res 2012;18:4895–902.
7. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 2012;18:1201–6.
8. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115–22.
9. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939–44.
10. Hugo HJ, Saunders C, Ramsay RG, Thompson EW. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia 2015;20:109–19.
11. Singh B, Berry JA, Vincent LE, Lucci A. Involvement of IL-8 in COX-2mediated bone metastases from breast cancer. J Surg Res 2006;134: 44–51.
12. Cordon-Cardo C.At the crossroad of tumorigenesis: drivers and hitchhikers. Hum Pathol 1999;30:1001–3.
13. Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, et al. Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A 2010;107:5681–6.
14. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012;188:21–8.
15. Yakar I, Melamed R, Shakhar G, Shakhar K, Rosenne E, Abudarham N, et al. Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol 2003;10:469–79.
16. Shakhar G, Ben-Eliyahu S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 1998;160:3251–8.
17. Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, Shakhar K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 2000;8:154–64.
18. Le CP, Nowell CJ, Kim-Fuchs C, Botteri E, Hiller JG, Ismail H, et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat Commun 2016;7:10634.
19. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008; 15:2042–52.
20. Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010;184: 2449–57.
21. Sorski L, Melamed R, Matzner P, Lavon H, Shaashua L, Rosenne E, et al. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through b-adrenoceptors blockade and COX2 inhibition. Brain Behav Immun 2016;58:91–8.
22. Melamed R, Rosenne E, Shakhar K, Schwartz Y, Abudarham N, Ben-Eliyahu S. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 2005;19:114–26.
23. Inbar S, Neeman E, Avraham R, Benish M, Rosenne E, Ben-Eliyahu S. Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E2 through reduced NK activity. PLoS One 2011;6:e19246.
24. Shaashua R. S-F, EK S, Ben-Eliyahu S.Surgical excision of a primary tumor enhances spontaneous metastasis of breast cancer through COX-2 and b-adrenergic pathways. New York, NY: Cold Spring Harbor Laboratory; 2015.
25. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1:628–38.
26. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 2011;29:2635–44.
27. Friis S, Riis AH, Erichsen R, Baron JA, Sorensen HT. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study. Ann Intern Med 2015;163:347–55.
28. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277–9.
29. Neil JR, Johnson KM, Nemenoff RA, Schiemann WP. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis 2008;29:2227–35.
30. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185–93.
31. Greenfeld K, Avraham R, Benish M, Goldfarb Y, Rosenne E, Shapira Y, et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun 2007;21:503–13.
32. Adhim Z, Matsuoka T, Bito T, Shigemura K, Lee KM, Kawabata M, et al. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer 2011;105:393–402.
33. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580–4.
34. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993;53:3241–5.
35. Boidot R, Vegran F, Jacob D, Chevrier S, Cadouot M, Feron O, et al. The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene 2010;29:2577–84.
36. Wang Y, He X, Ngeow J, Eng C. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet 2012;21:569–76.
37. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14:736–46.
38. Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi SI. Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 2004;32:649–61.
39. Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T, et al. Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. Endocr Relat Cancer 2007;14:279–92.
40. Schorr K, Furth PA. Induction of bcl-xL expression in mammary epithelial cells is glucocorticoid-dependent but not signal transducer and activator of transcription 5-dependent. Cancer Res 2000;60:5950–3.
41. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 2000;60:867–72.
42. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocor-ticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001;276:16649–54.
43. Sengupta S, Wasylyk B. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev 2001;15:2367–80.
44. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun 2007;21:901–12.
45. Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP. C-reactive protein and breast cancer: new insights from old molecule. Int J Breast Cancer 2015;2015:145647.
46. Nelson BH.CD20þ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010;185:4977–82.
47. Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003;52:715–38.
48. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405–13.
49. Gustafson MP, Lin Y, Bleeker JS, Warad D, Tollefson MK, Crispen PL, et al. Intratumoral CD14þ cells and circulating CD14þHLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2015;21:4224–33.
50. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239–52.
51. Matsumoto G, Omi Y, Lee U, Nishimura T, Shindo J, Penninger JM. Adhesion mediated by LFA-1 is required for efficient IL-12-induced NK and NKT cell cytotoxicity. Eur J Immunol 2000;30:3723–31.
52. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014; 64:e77–137.
53. Wattchow DA, De Fontgalland D, Bampton PA, Leach PL, McLaughlin K, Costa M. Clinical trial: the impact of cyclooxygenase inhibitors on gastrointestinal recovery after major surgery - a randomized double blind controlled trial of celecoxib or diclofenac vs. placebo. Aliment Pharmacol Ther 2009;30:987–98.
54. Group PS, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371: 1839–47.
55. Hazut O, Shaashua L, Benish M, Levi B, Sorski L, Benjamin B, et al. The effect of beta-adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis. Int J Clin Pharmacol Ther 2011;49:545–54.
56. Zmora O, Shaashua L, Gutman M, Ben-Eliyahu S. The perioperative use of a beta-adrenergic blocker and a COX-2 inhibitor in colorectal cancer patients for the prevention of cancer recurrence: a preliminary study assessing feasibility and safety. Brighton, United Kingdom: BBI;2016.
57. Ricon I, Hiller JG, Ben-Eliyahu S. The combined blockade of beta-Adrenoceptor and COX-2 during the perioperative period to improve long-term cancer outcomes. Int Anesthesiol Clin 2016; 54:72–91.
58. Cole SW, Hawkley LC, Arevalo JM, Cacioppo JT. Transcript origin analysis identifies antigen-presenting cells as primary targets of socially regulated gene expression in leukocytes. Proc Natl Acad Sci U S A 2011; 108:3080–5.
59. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, et al. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010;70:2296–306.